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Abstract
Background: Tuberculosis (TB) patients with multiple episodes of anti-TB treatment represent an important source
of TB transmission, as well as a serious threat to the control of drug resistant TB, due to the high risk of multidrug
and extensively drug resistance (MDR/XDR) and elongating infectiousness of this patient group. In this study we
analyzed the possible risk of development and transmission of MDR and XDR in TB patients with multiple episodes
of previous treatment history.
Methods: The study subjects were pulmonary TB patients who had at least two episodes of previous anti-TB
treatment. A total of 166 eligible patients were identified from 10 counties/districts distributed in east, west, north,
south and central China. Drug susceptibility test (DST) was performed by proportion method on LJ-media for the
1st line anti-TB drugs and a line probe assay was used to detect mutations related to resistance of the key 2nd-line
drugs. Genotyping of M. tuberculosis (Mtb) was performed with MIRU-VNTR and Spoligotyping.
Results: Resistances to 1st-line drugs was observed in 122 (73.5 %) of the 166 Mtb isolates with 97 (58.4 %) being
MDR-TB. Mutations relevant to 2nd-line drug resistance was seen in 63 isolates, including 35 MDR-TB isolates
(30 pre-XDR, 5 XDR-TB). The Spoligotyping revealed 83.1 % Mtb isolates belonged to the Beijing family. The MIRU-
VNTR based genotyping revealed 32 (19.3 %) of patients were infected with more than one strain. The number of
previous TB treatment episode was found being significantly associated with the risk of MDR-TB and XDR-TB.
Among the remaining 134 patients infected with a single Mtb strain, MIRU-VNTR revealed a high homogeneity of
strain especially within Beijing family despite the polymorphic variations along with geographic locations.
Conclusions: The high genetic relatedness and risk of MDR-TB and subsequent pre-XDR and XDR-TB among
repeatedly treated patients suggest the establishment of M/XDR Mtb in this specific patient population. It highlights
the urgent needs of providing DST of both 1st- and 2nd-line drugs before and during the medication in China’s
MDR-TB control program. Furthermore, the possibility of infection with multiple strains should also be considered
to be associated with the drug resistance, which calls for the modification of treatment regimen.
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Background
Multidrug-resistant tuberculosis (MDR-TB) and the even
much severe form, extensively drug resistant tubercu-
losis (XDR-TB), has emerged as a significant global
health concern. Of the world’s 12 million people living
with TB, an estimated 450,000 people had MDR-TB in
2013. MDR-TB is estimated to be present in 3.7 percent
of newly diagnosed patients with TB and 20 percent of
previously treated patients around the world. Thus, pre-
vious treatment for TB is a strong risk factor for having
MDR-TB [1]. This might be due to the treatment failure,
re-infection and co-morbidity with HIV/AIDS, diabetes
and other conditions [2–4]. Furthermore, the previously
treated patients remain contagious for longer periods
(if not fully cured). Therefore, they become one of the
high risk population for transmitting resistant Mtb, es-
pecially in regions lacking effective MDR-TB control
programs. Although a history of treatment is a risk factor
for the development of drug resistant TB has been well
recognized [5, 6], the impact of these patients on the
local drug resistant-TB situation is unknown in many
developing countries.
In China, of the 1,400,000 prevalent TB cases, the esti-
mated MDR-TB rate was 5.7 % for new and 25.6 % for
previously treated cases [7]. China’s TB control program
provides smear microscopy-based TB diagnosis and
anti-TB treatment free of charge to new patients and
retreating patients who have had one full course of anti-
TB treatment. Since TB patients with multiple episodes
of treatment do not meet the eligibility for free TB care
in China, and there are no standardization of TB med-
ical services for patients which failed on retreatment,
this population become a ‘neglected’ group [8]. However,
the intricate disease profile and unclear drug resistant
pattern of these patients brings about the urgent need
for a timely TB diagnosis, and an individualized anti-
TB treatment based on quality assured in vitro DST,
which is far beyond the capacity of China’s basic TB
health care units in county and district level. To accel-
erate proper diagnosis and treatment among patients
with multiple treatment episodes, it is important to
understand the occurrence of 1st- and 2nd -line drug
resistance in this group of patients. Additionally, identi-
fication of major clones and its genetic characteristics
in these patients will be necessary for monitoring the
epidemic and transmission of drug resistant Mycobac-
terium tuberculosis (Mtb) in the communities. For this
purpose, we conducted a multi-center study to investi-
gate the drug susceptibility and genetic characterization
of isolates from TB patients with multiple episodes of
treatment. Meanwhile, we analyzed whether an infec-
tion with multiple strains increased the risk of drug re-




This study was approved by the Fudan School of Public
Health Institutional Review Board. Written informed
consent was obtained from all patients who participated
in the study.
Study design
The study subjects were smear and culture positive pul-
monary TB patients who reported to have experience at
least two longer than 1 month anti-TB treatment
courses previously. They were identified from the patient
registry system from October 2009 to February 2011
respectively from 10 counties/districts in east, west, cen-
tral, north and south China. These patients are referred
to designated hospitals for MDR-TB diagnosis and treat-
ment in their respective administrative area. The eligible
subjects were interviewed during their treatment course
by the physician in the TB dispensaries. A structured
questionnaire was used to collect the demographic and
clinical information, including age, sex, HIV status,
duration, regimen, tests and examinations of previous
treatment, etc.
Samples and cultures
For each patient, sputum samples were collected before
the diagnosis of TB. The sputum smears were examined
with smear microscopy for the presence of acid-fast bacilli.
Samples were decontaminated and processed as described
previously [9] using a standard N-Acetyl L-cysteine
(NALC) combined with sodium hydroxide method. The
processed samples were inoculated on egg-based Lowen-
stein Jensen (LJ) media.
Drug susceptibility testing
Phenotypic antimicrobial susceptibilities were deter-
mined by the reference laboratory in the local desig-
nated TB hospital. The 1st-line drugs were tested
using the proportional method on LJ media. The
antibiotic concentrations in the medium were according to
international recommendations, 0.2 mg/L for isoniazid
(INH), 40 mg/L for rifampicin (RIF), 2.0 mg/L for etham-
butol (EMB), and 4.0 mg/L for streptomycin (SM). Bacterial
growth on drug-containing media exceeding 1 % of the
number of colonies on drug-free media were considered to
be resistant to the specific agent. According to the manu-
facturer’s protocol, the susceptibilities to the 2nd-line
drugs were determined using MTBDRsl assay (Hain
Lifescience GmbH, Germany).
DNA extraction
Chromosomal DNA was extracted by centrifuging Mtb
cultures and re-suspending the cell pellet in Tris-EDTA
buffer. Cells were then heat-killed at 95 °C for 45 min,
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cooled to room temperature and centrifuged again.
The supernatant containing chromosomal DNA was
collected [10].
Genetic characterization of drug resistance
Detection of mutations in the studied Mtb isolates15.
The previously reported drug resistance related mutation
was detected by DNA sequencing including the follow-
ing nine genes: rpoB (RIF), katG and inhA (INH), embB
(EMB), pncA (PZA), gyrA (FQs), rrs (KAN, CAP, and
AMK), eis (KAN) and tlyA (CAP). The previously re-
ported drug resistance-determining regions were
amplified using locus-specific primers5. Sequence
data generated by ABI 3130xl genetic analyzer were
reviewed for confidence levels using an ABI se-
quence scanner, and chromatograms were analyzed
for the presence or absence of mutations by com-
parison with published sequences of H37Rv using
the SeqMan alignment application of the DNAStar
Lasergene (version 8.0) program. All mutations were
confirmed by sequencing the reverse strand.
Spoligotyping
Spoligotyping was performed using a commercially
available spoligotyping kit (Isogen Bioscience BV) in
accordance with the manufacturer’s instructions. Strain
family was determined by comparing spoligotyping
patterns with the SpoligDB4 database. Beijing family
Mtb was defined as those hybridizing the last nine spacer
oligonucleotides (spacers 35 to 43) of the spoligotyping
pattern.
Typing by MIRU-VNTR
The MIRU-VNTR PCRs were performed on chromo-
somal DNA extracted from Mtb cultures (described
above). The PCR was designed to amplify a standard set
of 24 loci plus four loci (1982, 3232, 3820, and 4120) re-
ported to be specific to the Beijing genotype strain [11].
The genomic DNA extracted from each sample using
primers earlier described [12]. For each reaction, DNA
from the reference strain Mtb H37Rv was used as a posi-
tive control, and sterile water was used as a negative
control. PCR products were electrophoretically separated
on 2 % agarose gels, using a 100-bp DNA ladder as size
markers. From the gel images, the corresponding MIRU-
VNTR bands were interpreted as copy numbers based
on the reference table [11]. For any sample that showed
multiple bands at any of the MIRU-VNTR loci, the PCR
was repeated twice in order to confirm the results as
well as to rule out the possibility of contamination. Mul-
tiple strains infection were noted to be present if a single
sample had more than one PCR product at two or more
loci, or if two or more samples from the same patient
differed in copy numbers at two or more loci. Samples
in which copy numbers were different at a single locus
were considered to represent single strain evolution ra-
ther than multiple strains.
In combination with spoligotyping data, 24-loci MIRU-
VNTR digital profiles were compared to MIRUVNTRplus
(http://www.miru-vntrplus.org/MIRU/index.faces) for
family and code assignment.
Assignment to clonal complexes
Phylogenetical relationships existing between strains
from different areas were investigated by drawing Mini-
mum Spanning Trees (MST) based on 24 loci MIRU-
VNTR patterns. It summarized the phylogenetic links
between two MIRU profiles differing by genetic changes;
the length, the color and the representation of the
branches indicated the level of loci involved in changes.
Thick and thin solid lines showed single and double loci
changes, respectively, while dotted lines showed more
than two loci changes. Different colors highlighted
drug susceptibilities of strains. A clonal complex was
defined by at least two strains linked by no more
than two loci changes.
Statistical analysis
ANOVA test was applied for continuous variables and
Chi-square test for categorical variables. The Binary
Logistic Regression Model was used to calculate the OR
and 95 % CI of clustering proportion between groups
with different socio-demographic and clinical features. A
p value of < 0.05 was considered statistically significant.
Results
Socio-demographic and clinical characteristics
During the study periods, 166 previously treated TB pa-
tients whose sputum cultures were positive for Mtb were
enrolled (Table 1), including 130 (78.4 %) men and 36
(21.7 %) women with an average age of 45 ± 14.7 years
(range, 19 to 79 years). Seventy-eight of 166 (47.0 %) had
experienced two episodes of treatment, the remained 88
(53.0 %) experienced 3–5 treatment courses. Chest radio-
graphs showed cavitation in 69 patients (41.6 %), with
highest proportion of cavity observed in patients from
south areas (56.0 %). Concurrent diseases were noted in
13 (7.8 %) patients including 1 with lung cancer, 7 with re-
spiratory diseases and 5 for diabetes mellitus according to
the chart records.
Drug susceptibility profile and genetic mutation
By phenotypic drug susceptibility testing on the 1st-line
drug and HAINs MTBDRsl assay testing on 2nd-line drug,
Mtb isolates from a total of 165 (99.4 %) patients were re-
sistant to at least one of the antimicrobial agents tested.
Among 97 MDR-TB isolates, 35 isolates (36.1 %) addition-
ally had the mutations associated with the resistance to
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either FQs and/or the 2nd-line injectable drugs, with five
being resistant to both two groups and thus referred to
XDR-TB.
Of INH resistant Mtb isolates from 116 patients,
67.2 % contained the mutation in codon 315. All the RIF
resistance-related mutation were observed in the codon
531 (80.7 %), 526 (15.6 %) and 516 (3.7 %) of the rpoB
gene. Sequencing of the pncA gene revealed that 39
(23.5 %) isolates had alternations including 38 non-
synonymous point mutations and 1 large fragment inser-
tions or deletions. Mutations related to FQs resistance
included the mutation in codon 94 (78.0 %), codon 91
(7.3 %) and codon 90 (17.1 %) in gyrA gene. The 27 iso-
lates with the mutation related to the 2nd-line injective
drug resistance, contained A1401G (81.5 %), C1402T
(14.8 %) and G1484T (3.7 %) of rrs gene.
Strain family identification
Spoligotyping showed that Beijing family strains was the
predominant group representing 83.1 % (138 of 166) of
all isolates. Twenty four isolates were assigned to four
other families including T family (7.8 %), CAS (3.0 %),
Ural (1.8 %), H family (1.2 %) and MANU2 (0.6 %). Four
strains (2.4 %) could not be classified to any earlier re-
ported lineage thus were designated “ambiguous”.
Distributions of patients with multiple strain infection
and their clinical characteristics
Through 24 MIRU-VNTR-based genotyping plus 4 MIRU-
VNTR loci specific to Beijing family, 32 of these patients
were infected with multiple strains of Mtb, giving a preva-
lence of 19.3 % (95 % Cl: 14.0–26.0 %). Of these isolates,
12 (37.5 %) showed two alleles at one loci, 9 isolates
(28.1 %) had two alleles at two loci, 6 isolates (18.8 %) had
two alleles at three loci, 4 isolates (12.5 %) had two alleles
at four loci, and 1 isolate (3.1 %) had two alleles at six loci.
The socio-demographic features, as well as clinical
characteristics that were found in patients with a single
or multiple strain were compared in Table 2. MDR-TB
was found in 27 of 32 patients infected with multiple Mtb
Table 1 Socio-demographic and clinical characteristics of the 166 Chinese TB patients with multiple episodes of treatment history
Geographic locations
Variables West East Central North South Total
n = 22 n = 29 n = 38 n = 52 n = 25 n =166
Female sex 5 (22.7) 6 (20.7) 8 (21.1) 11 (21.2) 6 (24.0) 36 (21.7)
Age (mean ± SD) 46 ± 13.8 47 ± 13.9 45 ± 17.8 46 ± 14.5 42 ± 11.8 45 ± 14.7
Episodes of previous treatment history
=2 8 (36.4) 12 (41.4) 20 (52.6) 26 (50.0) 12 (48.0) 78 (47.0)
>2 14 (63.6) 17 (58.6) 18 (47.4) 26 (50.0) 13 (52.0) 88 (53.0)
Cavity 9 (40.9) 11 (37.9) 13 (34.2) 22 (42.3) 14 (56.0) 69 (41.6)
Concurrent disease 2 (9.1) 2 (6.9) 3 (7.9) 4 (7.7) 2 (8.0) 13 (7.8)
Drug resistant profile
MDR only 6 (27.3) 7 (24.1) 13 (34.2) 27 (51.9) 9 (36.0) 62 (37.3)
MDR-FQR 3 (13.6) 2 (6.9) 5 (13.2) 6 (11.5) 3 (12.0) 19 (11.4)
MDR-INJR 1 (4.5) 3 (10.3) 2 (5.3) 4 (7.7) 1 (4.0) 11 (6.6)
Other 1st DR 6 (27.3) 9 (31.0) 9 (23.7) 7 (13.5) 9 (36.0) 40 (24.1)
Other 2nd DR 3 (13.6) 0 (0) 0 (0) 0 (0) 0 (0) 3 (1.8)
1st-2nd DR 2 (9.1) 7 (24.1) 8 (21.1) 6 (11.5) 2 (8.0) 25 (15.1)
XDR 0 (0) 1 (3.4) 1 (2.6) 2 (3.8) 1 (4.0) 5 (3.0)
MDR multidrug resistance, XDR extensively drug resistance, FQR floroquinolones resistance, INJR injective drug resistance
Table 2 General characteristics of patients infected with single
strain or multiple strains
Multiple strains Single strain P*
n = 32 n = 134
Social-demographic
Age 50 ± 16.0 44 ± 14.3 0.063
Male (Sex) 23 71.9 101 75.4 0.683
BMI value
21 ± 4.2 19 ± 5.2
0.176
Clinical feature
SS+ 30 93.8 125 93.3 1
Cavity 19 59.4 50 37.3 0.023**
Treatment episode > 3 25 78.1 58 43.3 0.001**
MDR 27 84.4 70 52.2 0.001**
Pre-XDR 7 21.9 23 17.2 0.534
XDR 3 9.4 2 1.5 0.049**
*p value from the Chi-square test
**p < 0.05
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strains, which was significantly higher than those infected
with a single strain (84.4 %. vs. 52.2 %, p = 0.001), so were
the proportion of XDR-TB (9.4 %. vs. 1.5 %. p = 0.049). No
statistically significant difference was found regarding pre-
XDR although it exhibited a similar distribution between
two groups with multiple and single Mtb strains (21.9 %.
vs. 17.2 %, p = 0.534). Additionally compared to the pa-
tients with single strain infection, the patients with single
strain infection had a significantly higher proportion treat-
ment episodes more than 3 (78.1 %. vs. 43.3 %, p = 0.001)
and cavitation (59.4 %. vs. 37.3 %, p = 0.023).
Clustering features of patient infected with single strain
MIRU-VNTR genotyping of Mtb isolates from the 134
patients with single strain showed that these isolates were
related at ≥70 % similarity, especially for Beijing family
(similarity >85 %). A slight geographic difference in
MIRU-VNTR genotyping was observed, although the
strain cannot be differentiated specifically to the geo-
graphic location (Fig. 1). It was also found that 101 of 134
isolates had unique MIRU types, whereas 33 isolates pro-
duced 14 clusters with identical MIRU types with three
MIRU-VNTR patterns shared more than two areas.
Multivariate logistic regression analysis was applied
to understand the risk factors to clustering (Table 3).
Patients with three or more treatment episodes had a
significantly higher clustering proportion than others
(34.5 %. vs. 17.1 %; adjusted OR: 2.41; 95 % CI:
1.012–6.543). Additionally, MDR-TB patients pre-
sented a significant higher proportion of clustering than
those non-MDR-TB (34.3 %. vs. 15.0 %; adjusted OR:
2.43; 95 % CI: 1.007–6.471) However, neither other
socio-demographic and medical variable nor the alleles
conferring resistance to 1st- and 2nd-line anti-TB drugs
were significantly associated with clustering.
MIRU-VNTR defined clones and drug susceptibility
characteristics of Mtb isolates with single strain
infection
The 134 Mtb isolates from patient with a single strain
were separated by Bionumerics into 11 clonal complexes
(90 isolates) and singletons (44 isolates) with the default
stringent definition of the groups by sharing alleles at 27
of 28 loci. The most dominant clone was comprised by
67 Mtb isolates, which all belonged to the Beijing family
(Additional file 1).
Fig. 1 The mini spanning tree analysis of the 134 M.tb isolates from the patient with single strain infection. Each circle represents a unique
genotype and a single bigger circle represents the cluster containing more than two isolates. Different color indicated the different drug resistant
pattern. Note: MDR, multidrug resistance; XDR, extensively drug resistance; FQR, fluoroquinolones resistance; INJR, injective drug resistance; DS,
drug sensitive; DR, drug resistance
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The detailed information on drug resistance profiles of
Mtb isolates grouped by different clones is shown in
Table 4. The MDR only, pre-XDR-TB and XDR-TB was
mainly observed in clone 1, while clone 2, 3, 4, 5, 6, 10
and 11 also contain one or two isolates of M/XDR-TB.
In addition, we detected a large variety of drug
resistance-related genes associated with the 1st and 2nd
line drug resistance (such as katG, rpoB, gyrA, rrs and
eis) in the prevalent clones.
Discussion
In our study we observed a significantly high proportion
of drug resistance in the group of patients with multiple
treatment courses. It was found that almost all the Mtb
isolates in this study were resistant to at least one of
anti-TB drugs and 58.4 % was MDR, which were much
higher than that of newly treated and previously treated
TB patients reported in our previous studies [7, 13, 14].
This might be due to that a high proportion of subjects
have experienced more than two treatment courses. The
long duration of suboptimal anti-TB treatment could
impose a higher drug pressure driving the selection of
drug resistant Mtb strains. The present study demon-
strates a proportional association between the risk of
drug resistance and number of previous treatment ep-
isodes. In addition to 1st-line drug susceptibilities,
this study attempted to investigate also the 2nd- line
drug susceptibilities. Interestingly, the resistance to
FQs and 2nd-line injectable drugs were observed re-
spectively in 24.5 and 16.3 % of subjects and equally
distributed among the MDR-TB and other drug resistant
Mtb strains. This may suggest the clinical value of the
combined use of 2nd-line drug in treating the previously
treated TB patients as well as the implementation of rapid
and accurate DST of these anti-TB drugs.
Another important finding in this study is the high pro-
portion of infections with multiple Mtb strains (19.3 %)
among previously treated Chinese TB patients. Studies
from similar high-incidence settings in South Africa
showed multiple infection rates of 19 % [15], or 2.3 %
using IS6110 restriction fragment length polymorphism
(RFLP) [16]. The mixed-infection patient group had the
Table 3 Risk for clustering of Mtb isolates stratified by drug-resistant pattern, gene mutation and non-bacterial factors among the
TB patients with single strain infection
No. of isolates Unadjusted Adjusted by age, sex and areas
Total Clustered (%) OR* 95 % CI* OR* 95 % CI*
Socio and clinical factors
Sex
Female 33 7 (21.2) 1 1
Male 101 26 (25.7) 1.29 0.469–3.931 1.20 0.435–4.041
Treatment episode
=2 76 13 (17.1) 1 1
≥3 58 20 (34.5) 2.55 1.060–6.238** 2.41 1.012–6.543**
Sputum smear
Negative 9 2 (22.2) 1 1
Positive 125 31 (24.8) 1.15 0.205–11.94 1.12 0.201–12.02
Drug resistance and genetic mutation:
Other DR 60 9 (15.0) 1 1
MDR 70 24 (34.3) 2.45 1.008–6.363** 2.43 1.007–6.471**
preXDR/XDR 25 6 (24.0) 1.79 0.456–6.520 1.81 0.451–6.522
Drug resistant isolates with mutation in:
WT 38 7 (18.4) 1 1
katG 59 12 (20.3) 1.33 0.421–4.470 1.28 0.419–4.451
rpoB 55 21 (38.2) 2.74 0.943–8.622 2.64 0.873–8.953
pncA 39 8 (20.5) 1.14 0.317–4.197 1.15 0.313–4.221
gyrA 11 3 (27.3) 1.66 0.224–9.531 1.53 0.214–9.524
rrs 7 1 (14.3) 0.74 0.014–7.907 0.71 0.010–8.123
eis 4 0 (0) - -
MDR multidrug resistance, XDR extensively drug resistance
*OR and 95 % CI were calculated in the binary logistic regression model
**p < 0.05
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highest rate of MDR-TB, MDR plus FQs resistance and
XDR-TB (Table 4). Undetected multidrug-resistant strains
in a mixed infection may outcompete drug-susceptible
strains during antibiotic treatment [17]. In support of this
notion, mixed infection has been reported to be an
important risk factor for drug resistance in a high TB-
incidence region [18]. Inconsistent with an earlier re-
ported study [18], the clinical presentations in our study
appeared to be different between the patients with mul-
tiple and single strain infections. Patients infected with
multiple strains exhibited more clinical symptom (cavity,
smear positive) compared to those others. Since multiple
strain infections could alter initial presentation or re-
sponse to treatment, it should be taken into account on
the clinical course for individual patients. These results in-
dicate a lower proportion of strains sensitive to all drugs
and the highest proportion of strains resistant to at least
one drug in the mixed-infection group unequivocally.
Thus, the mixed-infection group represents an intermedi-
ate risk group which may contribute to an increased risk
of MDR. Therefore, early identification of patients with
dual infections would enable prompt therapy with an opti-
mized drug regimen increasing the cure rate.
MIRU-VNTR genotyping indicated that the degree of
Mtb genotypic heterogeneity did not vary significantly
between different geographical areas. This may be ex-
pected given the overwhelming dominance of the Beijing
family strain in most regions in China [19, 20]. Consist-
ent with previous reports [21–23], the results of geno-
typing indicate that Beijing family of strains is also
overrepresented in this population. While different from
the previous study [22], the member within Beijing family
exhibit the close-relatedness with similarity more than
80 % and the 11 clones were identified with the majority
clone comprised by 90 Mtb isolates, which all belong to
Beijing genotype. This might suggest some clones within
Beijing family might be responsible for the previously-
treated TB. Meanwhile, the significant higher proportion
of MDR-TB was observed in several clones than the
others. Furthermore, all the clones within Beijing family
contained 67.7 % of MDR-TB and 51.7 % of pre-XDR-TB
and 33.3 % of XDR-TB, which suggest the establishment
of 2nd-line drug resistant Mtb in the local setting. There-
fore, Monitoring of these clones through timely genotypic
analysis would provide a way to identify suspected MDR-
TB and XDR-TB cases more rapidly and ensure better tra-
cing of contacts, with the aim of containing these strains,
thereby avoiding a possible XDR-TB outbreak.
The molecular typing of Mtb has greatly improved
knowledge of TB epidemiology and enabled molecular
guided control of the disease. The Mtb isolates within
Beijing family showed a relatively high level of clustering
(35.2 %), suggesting active transmission, despite no signifi-
cantly difference with non-Beijing genotype. Furthermore,
three Beijing MIRU-VNTR clusters were simultaneously
observed in more than two areas, possibly due to its inter-
provincial transmission. This tendency suggests the poten-
tial of high transmissibility for some specific members of
Beijing family [17]. The active transmission of such sub-
groups may contribute to the ongoing epidemic of TB in
rural China and highlights the need for better control
measures to prevent the primary transmission. Addition-
ally, the high proportion of clustering pattern in cases with
previous treatment episode more than three times is also
a warning signal that indicates that inadequate previous
treatment increasing the risk of drug-resistance. Moreover,
Table 4 Drug susceptibilities profile and genetic mutation of the major clonal complexes in Mtb strains isolated from single
infection patients
Total. MDR only MDR-FQR MDR-INJR XDR katG rpoB pncA gyrA rrs eis
Clone 1 67 31 (46.3) 5 (7.5) 4 (6.0) 2 (3.0) 37 (55.2) 39 (58.2) 21 (31.3) 5 (7.5) 4 (6.0) 3 (4.5)
Clone 2 2 0 (0.0) 0 (0.0) 1 (50.0) 0 (0.0) 1 (50.0) 1 (50.0) 1 (50.0) 1 (50.0) 1 (50.0) 0 (0.0)
Clone 3 2 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0) 1 (50.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0)
Clone 4 2 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0) 2 (100.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0)
Clone 5 2 1 (50.0) 2 (100.0) 0 (0.0) 0 (0.0) 1 (50.0) 1 (50.0) 0 (0.0) 2 (100.0) 0 (0.0) 0 (0.0)
Clone 6 4 3 (75.0) 1 (25.0) 0 (0.0) 0 (0.0) 4 (100.0) 2 (50.0) 1 (25.0) 0 (0) 1 (25.0) 0 (0.0)
Clone 7 2 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0) 0 (0.0) 0 (0.0)
Clone 8 2 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0) 0 (0.0) 1 (50.0) 0 (0) 0 (0.0) 0 (0.0)
Clone 9 2 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0)
Clone 10 2 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0) 0 (0.0) 0 (0) 0 (0.0) 0 (0.0)
Clone 11 3 1 (33.3) 1 (33.3) 0 (0.0) 0 (0.0) 3 (100) 1 (33.3) 1 (33.3) 0 (0) 0 (0.0) 0 (0.0)
Singleton 44 11 (25.0)* 0 (0.0)* 1 (2.3) 0 (0.0)* 8 (18.2)* 7 (15.9)* 12 (27.3) 2 (4.5)* 1 (2.3) 0 (0.0)
MDR multidrug resistance, XDR extensively drug resistance, FQR fluoroquinolones resistance, INJR injective drug resistance
*p < 0.05 in comparison to the clone group
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the observation of significantly high clustering proportion
of MDR-TB isolates demonstrates the establishment of
MDR Mtb strain transmission and its contribution to the
MDR epidemics. Therefore, MDR-TB control programs in
China needs additional strategies such as establishing
referral system for patients at high risk of drug-resistant
TB, improving ability of diagnosis for drug-resistance in
TB clinics and hospitals, and providing individualized
treatment for drug-resistant TB patients.
There are some limitations of this study. Firstly, the
sample size might be not large enough for generalizing
the conclusions. Since the TB patient with multiple
treatment history is not eligible for the free treatment in
China’s DOTS program, it is not possible to identify
them in the TB surveillance system and therefore such a
limited number of subjects were enrolled in the present
study. However, despite the relatively small sample size,
the multiple-centered population-based study design will
ensure the representativeness of the study subjects to re-
flect those who were seeking TB care in the TB control
program during the study period, and thus were possible
to recommend to China’s MDR-TB control program.
Secondly, owing to the unavailability of the culture
specimen for most of subjects, we, instead, used line
probe assay to estimate the proportion of 2nd-line
drug resistance, which might underestimate the re-
sistance to 2nd-line drugs in this study. However,
based on the our previously reported paper [14], the
gene and its genetic mutation applied in the HAINs
DRsl kit proven to perform satisfactory to predicate
the 2nd-line drug susceptibilities, with the sensitivity
and specificity demonstrating up to 86.5 and 99.4 %
respectively.
Conclusions
This study contributes substantially to the growing
body of evidence that Mtb strains from patients with
multiple treatment courses exhibit a highly genetic re-
latedness and high risk of development MDR-TB and
subsequent pre-XDR-TB and XDR-TB. These findings
provide informative and fundamental evidences for
better understanding the biology of tuberculosis dis-
ease and contribute to a more refined approach to
control of M/XDR-TB globally, from diagnosis to
treatment and prevention.
Additional file
Additional file 1: MIRU-VNTR data of the Beijing family Mtb strain.
(XLSX 25 kb)
Abbreviations
MTB: Mycobacterium tuberculosis; MDR: Multidrug-resistant; INH: Isoniazid;
RIF: Rifampicin; STR: Streptomycin; EMB: Ethambutol; DST: Drug susceptibility
test.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YH carried out the data collection and molecular genotyping studies,
participated in the PCR and sequence alignment and drafted the manuscript.
SH, VD and JW has revised it critically for important intellectual content. YH,
QZ and JW was involved in all the microbiological research. BX, QZ and YH
participated in the conception and design, acquisition of data, its analysis
and interpretation. BX conceived the study, developed the design,
coordinated the implementation, and helped to revise the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
The study was financially supported by the Sweden-China (VR-NSFC) joint
project (PI, Biao Xu and Sven Hoffner, No. 81361138019) as well as grants
from National Natural Science Foundation of China (PI, Yi Hu, No. 81373063).
Author details
1Department of Epidemiology, School of Public Health, Fudan University, 138
Yi Xue Yuan Rd, Shanghai 200032, China. 2Key Laboratory of Public Health
Safety, Fudan University, Ministry of Education, Shanghai, China.
3Microbiology and Tumor Biology Center (MTC), Karolinska Institutet, S-171
77 Stockholm, Sweden. 4The Public Health Agency of Sweden, Solna,
Sweden. 5School of Public Health, Centre for Global Health, Karolinska
Institutet, Stockholm, Sweden.
Received: 14 November 2014 Accepted: 30 December 2015
References
1. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium
tuberculosis with extensive resistance to second-line drugs–worldwide,
2000–2004. MMWR Morb Mortal Wkly Rep. 2006;55(11):301–5.
2. Fisher-Hoch SP, Whitney E, McCormick JB, Crespo G, Smith B, Rahbar MH, et
al. Type 2 diabetes and multidrug-resistant tuberculosis. Scand J Infect Dis.
2008;40(11–12):888–93.
3. Isaakidis P, Das M, Kumar AM, Peskett C, Khetarpal M, Bamne A, et al.
Alarming levels of drug-resistant tuberculosis in HIV-infected patients in
metropolitan Mumbai, India. PLoS One. 2014;9(10):e110461.
4. Sergeev R, Colijn C, Murray M, Cohen T. Modeling the dynamic relationship
between HIV and the risk of drug-resistant tuberculosis. Sci Transl Med.
2012;4(135):135ra167.
5. Yang X, Li Y, Wen X, Wu G, Li X. Risk factors for drug resistance in
pulmonary tuberculosis inpatients. J Evid Based Med. 2010;3(3):162–7.
6. Migliori GB, Sotgiu G, Gandhi NR, Falzon D, DeRiemer K, Centis R, et al.
Drug resistance beyond extensively drug-resistant tuberculosis:
individual patient data meta-analysis. Eur Respir J. 2013;42(1):169–79.
7. Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, et al. National survey of
drug-resistant tuberculosis in China. N Engl J Med. 2012;366(23):2161–70.
8. Xu B, Zhao Q, Hu Y, Shi Y, Wang W, Diwan VK. Experiences in anti-tuberculosis
treatment in patients with multiple previous treatments and its impact on
drug resistant tuberculosis epidemics. Glob Health Action. 2014;7:24593.
9. Muhumuza J, Asiimwe BB, Kayes S, Mugyenyi R, Whalen C, Mugerwa RD, et al.
Introduction of an in-house PCR for routine identification of M. tuberculosis in
a low-income country. Int J Tuberc Lung Dis. 2006;10(11):1262–7.
10. De Almeida IN, Da Silva CW, Rossetti ML, Costa ER, De Miranda SS.
Evaluation of six different DNA extraction methods for detection of
Mycobacterium tuberculosis by means of PCR-IS6110: preliminary study.
BMC Res Notes. 2013;6:561.
11. Multilocus Variable Number Tandem Repeat Genotyping of Mycobacterium
tuberculosis, Technical Guide. [http://www.miru-vntrplus.org/MIRU/index.faces.
12. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rusch-Gerdes S, Willery E,
et al. Proposal for standardization of optimized mycobacterial interspersed
repetitive unit-variable-number tandem repeat typing of Mycobacterium
tuberculosis. J Clin Microbiol. 2006;44(12):4498–510.
13. Zhao LL, Chen Y, Chen ZN, Liu HC, Hu PL, Sun Q, et al. Prevalence and
molecular characteristics of drug-resistant Mycobacterium tuberculosis in
Hunan, China. Antimicrob Agents Chemother. 2014;58(6):3475–80.
14. Hu Y, Hoffner S, Wu L, Zhao Q, Jiang W, Xu B. Prevalence and genetic
characterization of second-line drug-resistant and extensively drug-resistant
Hu et al. BMC Infectious Diseases  (2016) 16:4 Page 8 of 9
Mycobacterium tuberculosis in Rural China. Antimicrob Agents Chemother.
2013;57(8):3857–63.
15. Warren RM, Victor TC, Streicher EM, Richardson M, Beyers N, Gey van Pittius
NC, et al. Patients with active tuberculosis often have different strains in the
same sputum specimen. Am J Respir Crit Care Med. 2004;169(5):610–4.
16. Richardson M, Carroll NM, Engelke E, Van Der Spuy GD, Salker F, Munch Z,
et al. Multiple Mycobacterium tuberculosis strains in early cultures from patients
in a high-incidence community setting. J Clin Microbiol. 2002;40(8):2750–4.
17. Behr MA. Tuberculosis due to multiple strains: a concern for the patient? A
concern for tuberculosis control? Am J Respir Crit Care Med. 2004;169(5):554–5.
18. van Rie A, Victor TC, Richardson M, Johnson R, van der Spuy GD, Murray
EJ, et al. Reinfection and mixed infection cause changing Mycobacterium
tuberculosis drug-resistance patterns. Am J Respir Crit Care Med.
2005;172(5):636–42.
19. Wang W, Hu Y, Mathema B, Jiang W, Kreiswirth B, Xu B. Recent transmission
of W-Beijing family Mycobacterium tuberculosis in rural eastern China. Int J
Tuberc Lung Dis. 2012;16(3):306–11.
20. Hu Y, Ma X, Graviss EA, Wang W, Jiang W, Xu B. A major subgroup of
Beijing family Mycobacterium tuberculosis is associated with multidrug
resistance and increased transmissibility. Epidemiol Infect. 2011;139(1):130–8.
21. Panaiotov S, Bachiyska E, Yordanova S, Atanasova Y, Brankova N, Levterova
V, et al. Beijing Lineage of MDR Mycobacterium tuberculosis in Bulgaria,
2007–2011. Emerg Infect Dis. 2014;20(11):1899–901.
22. Liu Y, Tian M, Wang X, Wei R, Xing Q, Ma T, et al. Genotypic diversity
analysis of Mycobacterium tuberculosis strains collected from Beijing in 2009,
using spoligotyping and VNTR typing. PLoS One. 2014;9(9):e106787.
23. Faksri K, Chaiprasert A, Pardieu C, Casali N, Palaga T, Prammananan T, et al.
Heterogeneity of phenotypic characteristics of the modern and ancestral
Beijing strains of Mycobacterium tuberculosis. Asian Pac J Allergy Immunol.
2014;32(2):124–32.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Hu et al. BMC Infectious Diseases  (2016) 16:4 Page 9 of 9
